No Need to Rush Into Adding Drugs for Dementia-Related Agitation: Canadian Trial Tests Structured Care

When people with dementia exhibit agitation, wandering, or aggressive behavior, care teams often need to control risks quickly, which may lead to multiple psychiatric medications being added one after another. A Canadian randomized controlled trial proposes another pathway: first identify individual triggers and use non-drug interventions, adding medications in a predetermined sequence only when necessary. This approach may reduce some unnecessary medication use early in treatment.

The 12-week trial, named StaN, was led by Canada's Centre for Addiction and Mental Health and conducted across five inpatient units and seven long-term care facilities. It enrolled 185 patients with Alzheimer's disease who had symptoms of agitation. Participants were assigned in a one-to-one ratio to either an integrated care pathway or usual care. The study tracked both scores on the Cohen-Mansfield Agitation Inventory and the proportion of participants receiving more than one psychiatric medication.

The integrated pathway was not a single therapy, but a clinical process that established a fixed sequence for assessment and decision-making. Care teams first used personalized measures such as music, social interaction, and purposeful activities. When needed, medications were then introduced sequentially according to standardized assessments and predefined decision points. The aim was not to eliminate medications entirely, but to avoid adding multiple prescriptions simultaneously before patients' needs had been clarified.

The paper's results showed no significant between-group difference in changes on the agitation scale with either care approach, in either the inpatient or long-term care groups. This indicates that the structured pathway did not show a signal of worse agitation control. However, a finding that did not reach statistical significance is not equivalent to formal proof that the two approaches were equally effective, and this distinction must be preserved when interpreting the results.

Regarding medication use, the integrated pathway's advantage appeared mainly early on: psychiatric polypharmacy rates were lower among inpatients at weeks 3, 4, and 6, and among long-term care residents at week 3. By week 12, the difference between the two groups was no longer significant. In other words, the trial more strongly supports the conclusion that this process can delay or reduce the addition of multiple medications early in treatment, but it does not yet demonstrate that it can produce a sustained reduction in medication use over a longer period.

All study settings were Canadian inpatient or long-term care facilities affiliated with academic hospitals, and follow-up lasted only 12 weeks. Whether the findings can be extended to general community settings, non-academic long-term care facilities, and different healthcare systems remains to be verified. The research team's next step is to expand the settings in which the pathway is used and assess longer-term outcomes including caregiver burden, quality of life, and falls. Until those data are available, this study is better viewed as providing an evidence-based starting point for “care first, add medications later” than as declaring that a new standard of care has been established.